trending Market Intelligence /marketintelligence/en/news-insights/trending/SdaCWQNAayIDQu8kjMahRg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

ProQR appoints chief medical officer to target gene-based eye therapies

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


ProQR appoints chief medical officer to target gene-based eye therapies

ProQR Therapeutics N.V. appointed Aniz Girach as its chief medical officer, and made other management changes, as it seeks to develop its pipeline of products for inherited eye diseases.

The Netherlands-based biopharmaceutical company said Girach previously served as the chief medical officer of Nightstar Therapeutics plc where he oversaw the development of gene therapies for inherited retinal disorders. Earlier in October, ProQR said it will acquire the exclusive worldwide license for a gene-based therapy called QR-1123 from Ionis Pharmaceuticals Inc.

Elsewhere, ProQR promoted CFO Smital Shah to the role of chief business and financial officer.

The company also appointed Tiffany Burt as vice president and head of commercial, while Lisa Hayes was appointed as vice president of investor relations and corporate communications.

In addition, ProQR said that at the end of the year René Beukema will retire as chief corporate development officer, general counsel and board member while Robert Cornelisse will retire as chief people and organization.

The company added that the two will not be replaced in the management.